HBOT Adverse Event Reporting to the FDA

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

The Undersea & Hyperbaric Medical Society (UHMS) lists 14 primary indications for HBOT, including air or gas embolism and carbon monoxide poisoning (UHMS, 14th Edition).
Gas embolism from breath-holding can occur after an ascent of as little as one meter in diving (Moon, 2020).
The FDA recommends UHMS-accredited facilities for specific illnesses treated with HBOT (UHMS News, 2023).
Continuous IV infusion of oxygen at 10 mL/min has been tolerated in humans, but 20 mL/min caused symptoms (Moon, 2020).

Reporting adverse events in Hyperbaric Oxygen Therapy (HBOT) to the FDA is an important step in ensuring patient safety and treatment efficacy. HBOT involves breathing 100% oxygen in a special pressurized chamber. The Undersea & Hyperbaric Medical Society (UHMS) plays a crucial role in defining and supporting the accepted uses of HBOT. The UHMS lists 14 primary indications for hyperbaric oxygen therapy, covering a range of conditions from air or gas embolism to severe anemia. The FDA itself recommends that patients seek treatment at UHMS-accredited hyperbaric facilities for specific illnesses, underscoring the importance of these established guidelines. For instance, continuous intravenous infusion of oxygen at 10 mL/min has been reported as well tolerated in humans, while an infusion rate of 20 mL/min caused symptoms, highlighting the need for precise medical oversight in such treatments. Understanding these guidelines and the mechanisms of HBOT helps in identifying and reporting any unexpected or negative outcomes. See the severe anemia evidence atlas for the full study-by-study evidence breakdown.

What is Hyperbaric Oxygen Therapy (HBOT)?

Hyperbaric oxygen therapy, or HBOT, is a medical treatment where a patient breathes 100% oxygen inside a pressurized chamber. This process allows the body to absorb a much higher amount of oxygen than it would at normal atmospheric pressure. The increased oxygen levels can help in various physiological processes, including healing and fighting infections. Our understanding of HBOT has evolved over time, with the Undersea & Hyperbaric Medical Society (UHMS) providing a clear definition and regularly updated lists of accepted indications for the therapy. These indications are based on extensive research and clinical experience, ensuring that HBOT is used for conditions where it has demonstrated benefit.

The UHMS Definition of HBOT

The UHMS, a leading authority in hyperbaric medicine, formally defines hyperbaric oxygen therapy. This definition is critical for standardizing the application of HBOT across different medical settings. It ensures that healthcare providers and patients understand what HBOT entails and what it aims to achieve. The UHMS also publishes comprehensive reports outlining the indications for HBOT, which serve as a foundational guide for practitioners worldwide. These reports are meticulously compiled by committees of experts in the field.

Evolution of HBOT Indications

The list of conditions for which HBOT is considered an appropriate treatment has been refined over many years. The UHMS periodically updates its "Hyperbaric Oxygen Therapy Indications" report. For example, the 14th Edition of this report outlines the recognized uses for the treatment, building upon previous editions like the 13th Edition. These updates reflect new research findings, clinical experience, and ongoing advancements in medical science. The purpose of these editions is to provide evidence-based guidance to the medical community, helping to ensure that HBOT is applied effectively and safely. The report covers a wide array of conditions, each with detailed explanations and supporting evidence.

How HBOT Works in Practice

Inside a hyperbaric chamber, the atmospheric pressure is increased, often to two or three times normal air pressure. At the same time, the patient breathes pure oxygen through a mask or hood. This combination of increased pressure and high oxygen concentration causes oxygen to dissolve more readily into the blood plasma, cerebrospinal fluid, and other body fluids. This allows oxygen to reach areas that might be poorly perfused or oxygen-deprived due to injury or disease. The enhanced oxygen delivery can reduce swelling, stimulate new blood vessel growth, and aid in the body's natural healing processes. The UHMS guidelines help practitioners understand the optimal pressures and durations for different indications, ensuring treatment protocols are consistent and effective. Our analysis of the UHMS documents shows a commitment to rigorous scientific review in establishing these protocols.

Importance of Adhering to Guidelines

Adhering to the established UHMS indications is paramount for the safe and effective use of HBOT. Treating conditions not recognized by the UHMS could expose patients to unnecessary risks without proven benefits. The UHMS guidelines are not just a list of conditions; they represent a consensus of expert opinion and scientific evidence on when and how HBOT should be administered. This structured approach helps to minimize adverse events and maximize the therapeutic potential of HBOT. The regular updates to the "Hyperbaric Oxygen Therapy Indications" report mean that practitioners have access to the most current and validated information available. This ongoing commitment to updating best practices is a cornerstone of responsible medical care in hyperbaric medicine.

What are the FDA-Recognized Indications for HBOT?

The FDA plays a critical role in overseeing medical devices and therapies in the United States, and it specifically acknowledges the importance of proper HBOT administration. The FDA recommends UHMS-accredited hyperbaric facilities for treating specific illnesses, aligning its guidance with the expert consensus provided by the Undersea & Hyperbaric Medical Society. This recommendation helps patients identify facilities that adhere to high standards of care and utilize HBOT for conditions where its efficacy is well-established. The UHMS, through its various editions of "Hyperbaric Oxygen Therapy Indications," provides a comprehensive list of these recognized conditions, ensuring that practitioners have clear guidance on appropriate applications.

The UHMS List of Primary Indications

The UHMS lists 14 primary indications for hyperbaric oxygen therapy in its 14th Edition of "Hyperbaric Oxygen Therapy Indications." These indications are the core conditions for which HBOT is considered an accepted and often crucial treatment. When we reviewed the detailed list, we found it to be a testament to the diverse applications of this therapy. These conditions are backed by significant research and clinical experience, making them the standard for appropriate HBOT use.

The 14 primary indications include:

Air or Gas Embolism: This condition involves gas bubbles entering the bloodstream, which can be life-threatening. HBOT helps to reduce the size of these bubbles.
Arterial Insufficiencies: This category includes specific conditions like Central Retinal Artery Occlusion, where blood flow to an artery is blocked.
Selected Problem Wounds: HBOT is used to enhance healing in certain types of chronic or non-healing wounds.
Carbon Monoxide Poisoning: One of the most well-known uses, HBOT helps to quickly remove carbon monoxide from the body and deliver vital oxygen.
Clostridial Myonecrosis (Gas Gangrene): A severe bacterial infection where HBOT helps to fight the bacteria and preserve tissue.
Compromised Grafts and Flaps: HBOT can improve the chances of survival for tissues that have been transplanted or surgically rearranged.
Acute Traumatic Ischemias: Conditions like crush injuries and compartment syndrome, where blood flow is severely restricted.
Decompression Sickness: A condition affecting divers when they ascend too quickly, causing gas bubbles to form in the body.
Delayed Radiation Injuries: HBOT helps to heal tissues damaged by radiation therapy, which can manifest months or years after treatment.
Sudden Sensorineural Hearing Loss: A rapid loss of hearing that can sometimes be improved with HBOT.
Intracranial Abscess: A collection of pus within the brain, where HBOT can be an adjunctive treatment.
Necrotizing Soft Tissue Infections: Severe, rapidly spreading infections that destroy muscle, fat, and fascia.
Refractory Osteomyelitis: A persistent bone infection that does not respond to standard treatments.
Severe Anemia: In cases where a patient cannot receive a blood transfusion, HBOT can provide life-sustaining oxygen.
Thermal Burns: HBOT can be an adjunctive therapy in the treatment of severe burns.

These conditions represent the consensus of the hyperbaric medical community on where HBOT offers clear therapeutic benefits. The detailed discussions for each indication are found within the UHMS "Hyperbaric Oxygen Therapy Indications" reports, such as the 14th Edition.

The FDA's Endorsement of UHMS Accreditation

The FDA's recommendation for UHMS-accredited facilities is a significant endorsement of the society's standards. This guidance helps patients and healthcare providers make informed decisions about where to seek HBOT treatment. It implies that facilities meeting UHMS accreditation standards are more likely to provide safe and effective care for the recognized indications. The UHMS Hyperbaric Facility Accreditation Program ensures that clinics adhere to strict protocols for equipment, staff training, and patient safety. This alignment between the FDA and UHMS helps to ensure a consistent quality of care across the country. Patients seeking HBOT treatment for these specific conditions can look for the UHMS accreditation as a mark of quality and adherence to best practices.

Beyond the Recognized Indications

While the UHMS and FDA focus on these recognized indications, it is important to remember that not all uses of HBOT are equally supported by scientific evidence. The UHMS 13th Edition states, "No responsibility is assumed by the Publisher or Editor for any injury and or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, product, instructions, or ideas contained in the material herein." This highlights the importance of relying on established guidelines and consulting with qualified medical professionals. Patients should always verify that any proposed HBOT treatment aligns with the officially recognized indications and is performed in an accredited facility. Our commitment at HBOT Finder is to provide clear, evidence-based information, and this includes emphasizing the importance of these official recommendations. For a current look at where research—and adverse-event tracking—stands on one of the highest-volume off-label uses, see HBOT for Long COVID in 2026: Where Studies Stand. See detailed Shamir long-COVID RCT analysis for the full Shamir-RCT methodology analysis.

How Do Air or Gas Embolisms Relate to HBOT?

Air or gas embolism is a critical medical emergency where gas bubbles enter the arteries or veins, and hyperbaric oxygen therapy is a primary treatment for it. Gas embolism occurs when gas bubbles are introduced into the circulatory system, leading to blockages or other severe complications. The immediate goal of HBOT in these cases is to reduce the size of the gas bubbles and increase oxygen delivery to tissues that may be deprived. This rapid intervention is crucial because even small volumes of gas can have significant impacts, especially when they enter arterial circulation.

Understanding Gas Embolism

Gas embolism can manifest in two main forms: arterial gas embolism (AGE) and venous gas embolism (VGE). Richard E. Moon, in his 2020 article "Hyperbaric Oxygen Therapy Indications: Air or Gas Embolism," provides a detailed explanation of these conditions. He states, "Gas embolism occurs when gas bubbles enter arteries or veins. Arterial gas embolism (AGE) was classically described during submarine escape training, in which pulmonary barotrauma occurred during free ascent after breathing compressed gas at depth. Pulmonary barotrauma and gas embolism due to breath holding can occur after an ascent of as little as one meter." This highlights the fact that even seemingly minor changes in pressure, such as an ascent of just one meter, can trigger serious conditions like pulmonary barotrauma and gas embolism if proper diving procedures are not followed.

Causes of Gas Embolism

While diving is a classic cause, gas embolism can result from various medical procedures and injuries. Moon's research outlines numerous scenarios:

Diving-related: Beyond submarine escape training, AGE has been linked to normal ascent in divers with underlying lung conditions like bullous disease and asthma. Venous gas embolism (VGE) is also common after compressed gas diving.
Trauma: Blast injuries, both in and out of water, can cause pulmonary barotrauma. Penetrating chest trauma can also lead to gas embolism.
Medical Procedures: Accidental intravenous air injection, cardiopulmonary bypass accidents, needle biopsy of the lung, hemodialysis, and central venous catheter placement or disconnection are all potential causes. Gastrointestinal endoscopy, arthroscopy, and bronchoscopy have also been implicated.
Surgical Procedures: Procedures where the surgical site is under pressure, such as laparoscopy, transurethral surgery, vitrectomy, endoscopic vein harvesting, and hysteroscopy, can lead to air embolism. Massive VGE can also occur if surgical wounds are elevated above the heart, causing subatmospheric pressure in adjacent veins. This has been observed in sitting craniotomy, cesarean section, prostatectomy, spine surgery, hip replacement, liver resection, liver transplantation, and dental implant insertion.
Other Causes: Hydrogen peroxide irrigation or ingestion, cardiopulmonary resuscitation, percutaneous hepatic puncture, blowing air into the vagina during orogenital sex, and sexual intercourse after childbirth are also noted as potential causes.

The Impact of Gas Bubbles

The severity of symptoms depends on the volume and location of the gas bubbles. While intravenous injection of air can often be asymptomatic, intra-arterial injection of even small volumes can cause significant clinical deficits. Moon's research indicates that "Injection of up to 0.5-1 mL/kg has been tolerated in experimental animals." However, in humans, the threshold for symptoms can be lower. He further notes, "Continuous IV infusion of oxygen at 10 mL/min has been reported as well tolerated, while 20 mL/min caused symptoms." This shows a clear dose-response relationship, where higher volumes or rates of gas introduction are more likely to cause clinical abnormalities compared to constant infusions.

How HBOT Treats Gas Embolism

HBOT addresses gas embolism by using increased pressure to reduce the size of the gas bubbles in the bloodstream. According to Undersea & Hyperbaric Medical Society HBO Indications, this reduction in bubble size helps to clear blockages in blood vessels. The high partial pressure of oxygen also helps to oxygenate tissues that were deprived of blood flow due to the embolism. This dual action makes HBOT a critical and often life-saving treatment for both arterial and venous gas embolisms. The therapy not only physically shrinks the bubbles but also provides the necessary oxygen to prevent or reverse tissue damage, particularly in sensitive organs like the brain and heart.

What Specific Conditions Does UHMS Recognize for HBOT?

The Undersea & Hyperbaric Medical Society (UHMS) recognizes a broad spectrum of medical conditions for which hyperbaric oxygen therapy (HBOT) is an accepted treatment. These specific conditions are meticulously detailed in their "Hyperbaric Oxygen Therapy Indications" reports, such as the 14th Edition, which serves as a comprehensive guide for medical professionals. The inclusion of a condition in this list means that there is sufficient scientific evidence and clinical consensus to support the use of HBOT as a beneficial or even crucial therapy. Our review of these guidelines shows a commitment to evidence-based practice across various medical specialties.

Chronic and Acute Conditions

The UHMS list covers both acute, emergency conditions and chronic, ongoing issues. This shows the versatility of HBOT in addressing different types of medical challenges.

Acute Traumatic Ischemias

Acute traumatic ischemias refer to conditions where trauma leads to a sudden reduction in blood flow to tissues, often threatening tissue viability. This includes severe injuries like crush injuries, where significant pressure damages blood vessels and restricts circulation. Another example is compartment syndrome, where swelling within a confined muscle compartment cuts off blood supply. HBOT can be an invaluable adjunctive treatment in these scenarios, as it helps to increase oxygen delivery to the compromised tissues, reduce swelling, and prevent further tissue death. The goal is to preserve limbs and maximize recovery after severe trauma.

Delayed Radiation Injuries

Radiation therapy, while effective against cancer, can sometimes cause damage to healthy tissues, leading to delayed radiation injuries. These injuries can manifest months or even years after treatment and include conditions like soft tissue and bony necrosis (tissue death). HBOT is recognized for its ability to promote healing in these damaged tissues. It stimulates the growth of new blood vessels and enhances the body's natural repair mechanisms, helping to restore blood flow and oxygen to irradiated areas. This can significantly improve the quality of life for patients suffering from the long-term side effects of radiation.

Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss (SSNHL) is a rapid and unexplained loss of hearing, typically in one ear. While the exact cause is often unknown, it is thought to involve damage to the inner ear's sensory cells or nerve pathways. HBOT has been recognized as a treatment option for SSNHL, particularly when administered shortly after the onset of symptoms. The increased oxygen delivery to the inner ear structures may help to reduce inflammation, improve circulation, and support the recovery of damaged hair cells or nerve function. The UHMS 14th Edition discusses the role of HBOT in this context.

Intracranial Abscess

An intracranial abscess is a collection of pus within the brain, usually caused by a bacterial or fungal infection. This condition is serious and requires prompt medical attention, often involving antibiotics and surgical drainage. HBOT is considered an adjunctive therapy for intracranial abscesses. The high oxygen levels delivered during HBOT can enhance the killing power of certain antibiotics against anaerobic bacteria, which thrive in low-oxygen environments. It also helps to improve the immune response and reduce swelling within the brain, contributing to better outcomes for patients with this severe infection.

Necrotizing Soft Tissue Infections

Necrotizing soft tissue infections (NSTIs), such as necrotizing fasciitis, are aggressive and rapidly spreading bacterial infections that destroy muscle, fat, and fascia (the connective tissue surrounding muscles). These infections are life-threatening and require immediate surgical removal of dead tissue along with strong antibiotics. HBOT is a critical adjunctive treatment for NSTIs. The high oxygen levels help to kill anaerobic bacteria, which are often involved in these infections, and improve the effectiveness of antibiotics. HBOT also supports the body's immune response and helps to demarcate healthy tissue from infected tissue, aiding surgical debridement. The UHMS clearly outlines its role in managing these severe infections.

Refractory Osteomyelitis

Osteomyelitis is an infection of the bone, which can be challenging to treat, especially when it becomes chronic or "refractory," meaning it does not respond to standard antibiotics and surgery. Refractory osteomyelitis can lead to persistent pain, bone destruction, and even amputation. HBOT is recognized as an important adjunctive therapy for this condition. It enhances the delivery of oxygen to infected bone, which can be poorly vascularized, thereby improving antibiotic penetration and stimulating the body's healing processes. HBOT also promotes the formation of new blood vessels and bone, aiding in the resolution of the chronic infection.

Severe Anemia

Severe anemia is a condition where the blood lacks enough healthy red blood cells to carry adequate oxygen to the body's tissues. In certain critical situations, such as when a patient cannot receive a blood transfusion due to religious beliefs or severe adverse reactions, HBOT can be life-sustaining. HBOT increases the amount of dissolved oxygen in the blood plasma, allowing the body to receive essential oxygen even with a reduced red blood cell count. This temporary measure can bridge the gap until the underlying cause of anemia is addressed or other solutions become available.

Adjunctive Therapy for Thermal Burns

Thermal burns, especially severe ones, can lead to extensive tissue damage, compromised circulation, and increased risk of infection. HBOT is recognized as an adjunctive therapy in the treatment of thermal burns. It can help reduce swelling, improve blood flow to the burned areas, and promote wound healing. The increased oxygen levels can also enhance the body's ability to fight infection and support the survival of damaged but salvageable tissue. This can lead to faster healing times and potentially better functional and cosmetic outcomes for burn patients. The UHMS 14th Edition includes a section specifically addressing this application.

These diverse indications demonstrate the broad therapeutic potential of HBOT when applied according to established, evidence-based guidelines. The UHMS provides these detailed indications to ensure that HBOT is used responsibly and effectively, contributing to improved patient outcomes across various medical disciplines. For more details, see UHMS Hyperbaric Oxygen Therapy Indications 14th Edition.

Why is UHMS Accreditation Important?

UHMS accreditation is a crucial benchmark for quality and safety in hyperbaric oxygen therapy (HBOT). The FDA specifically recommends facilities that are UHMS-accredited, which underscores the importance of this designation. For patients and healthcare providers, UHMS accreditation offers assurance that a facility meets rigorous standards, ensuring that HBOT is administered effectively and safely. This accreditation process goes beyond basic licensing requirements, delving into the specifics of hyperbaric medicine practice.

Ensuring Safety and Efficacy Standards

Accreditation by the Undersea & Hyperbaric Medical Society ensures that facilities meet certain standards for safety and efficacy in HBOT. These standards cover a wide range of operational aspects, from the design and maintenance of hyperbaric chambers to the training and qualifications of the medical staff. When a facility achieves UHMS accreditation, it signals that it has undergone a thorough review process by experts in the field. This review evaluates compliance with best practices for patient care, emergency protocols, and equipment safety. The goal is to minimize risks associated with hyperbaric treatment and maximize its therapeutic benefits.

The UHMS Hyperbaric Facility Accreditation Program

The UHMS Hyperbaric Facility Accreditation Program is a comprehensive system designed to evaluate and certify hyperbaric medicine centers. The program outlines specific requirements that facilities must meet to achieve accreditation. These requirements are detailed and cover areas such as:

Personnel Qualifications: Ensuring that physicians, nurses, and technicians involved in HBOT have the appropriate training, certifications, and experience in hyperbaric medicine.
Equipment Standards: Verifying that hyperbaric chambers and associated equipment are properly maintained, calibrated, and meet safety specifications. This includes regular inspections and adherence to engineering codes.
Patient Care Protocols: Reviewing the facility's procedures for patient assessment, treatment planning, emergency response, and documentation. This ensures consistent and high-quality care delivery.
Facility Safety: Assessing the overall safety of the hyperbaric environment, including fire safety measures, ventilation, and oxygen handling procedures.
Quality Assurance: Requiring facilities to have ongoing quality improvement programs to monitor outcomes and continuously enhance their services.

When we consider the FDA's recommendation, it highlights the trust placed in the UHMS's ability to establish and enforce these high standards. This is not merely a formality; it is a commitment to patient well-being and consistent care.

Benefits for Patients and Providers

For patients, choosing a UHMS-accredited facility means they are more likely to receive care that aligns with the latest evidence-based practices and safety guidelines. It provides peace of mind, knowing that the facility has been vetted by an independent, expert organization. According to FDA Recommendation for UHMS-Accredited Facilities, this recommendation helps steer patients towards reputable providers.

For providers, achieving UHMS accreditation demonstrates a commitment to excellence and can enhance a facility's reputation. It also helps to standardize care, reduce liability risks, and foster a culture of continuous improvement. The accreditation process itself can be a valuable learning experience, helping facilities identify areas for enhancement and ensuring they are up-to-date with best practices in hyperbaric medicine. In our experience, facilities that pursue accreditation often show a deeper dedication to patient safety and clinical quality.

Addressing Concerns and Promoting Best Practices

The importance of accreditation also relates to managing the inherent risks of medical procedures. As stated in the UHMS 13th Edition, "No responsibility is assumed by the Publisher or Editor for any injury and or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, product, instructions, or ideas contained in the material herein." This disclaimer, while standard, underscores the need for every precaution and adherence to established protocols. Accreditation helps ensure that these precautions are in place. By upholding rigorous standards, UHMS accreditation works to mitigate potential risks and ensure that HBOT is administered under optimal conditions, thereby promoting the best possible outcomes for patients.

How Can I Find FDA-Cleared HBOT Devices?

Finding FDA-cleared HBOT devices is a crucial step for clinics and patients alike to ensure that the equipment used for hyperbaric oxygen therapy meets federal safety and effectiveness standards. The U.S. Food & Drug Administration (FDA) maintains databases where information about cleared medical devices, including hyperbaric chambers, is publicly accessible. This transparency allows for informed decisions regarding the equipment utilized in HBOT treatments. Relying on FDA-cleared devices is a fundamental aspect of providing safe and compliant hyperbaric care.

Navigating the FDA's 510(k) Premarket Notification Database

The primary resource for identifying FDA-cleared medical devices is the agency's 510(k) Premarket Notification database. This database contains information on devices that have demonstrated substantial equivalence to a legally marketed predicate device. This means they have been reviewed by the FDA and found to be as safe and effective as existing devices. Searching this database can help identify hyperbaric chambers and related equipment that have undergone this rigorous FDA review process.

How to Search the Database

To find FDA-cleared HBOT devices, one can typically use the FDA's online search tools. While the exact interface may vary over time, the general process involves:

Accessing the Database: Navigate to the FDA's medical device databases, specifically the 510(k) Premarket Notification section. A direct link to an example of a 510(k) notification is provided at 510(k) Premarket Notification.
Using Search Terms: Enter relevant search terms such as "hyperbaric chamber," "hyperbaric oxygen therapy," or specific manufacturer names if known.
Filtering Results: The database often allows for filtering by device type, applicant, or date.
Reviewing Notifications: Each entry will typically include details about the device, the manufacturer, and the date of clearance. This information confirms that the device has passed the FDA's premarket review.

For example, searching for a specific ID like 'k021690' would show a particular 510(k) premarket notification for a hyperbaric device. This unique identifier allows for precise tracking of specific device clearances. Our team regularly consults this database to verify the regulatory status of various HBOT equipment.

Understanding 510(k) Clearance vs. Approval

It is important to understand the distinction between 510(k) clearance and FDA approval. Most medical devices, including hyperbaric chambers, go through the 510(k) clearance process. This means the device is substantially equivalent to a device already on the market (a predicate device). FDA approval, on the other hand, is generally reserved for higher-risk devices that go through a Premarket Approval (PMA) process, which requires more extensive clinical data. For HBOT devices, 510(k) clearance is the standard regulatory pathway, indicating that the device is considered safe and effective for its intended use.

Types of Hyperbaric Chambers

There are generally two main types of hyperbaric chambers used in HBOT: monoplace and multiplace chambers. Both types can receive FDA clearance.

Monoplace Chambers: These chambers are designed for a single patient. The patient lies inside the chamber, which is then pressurized with 100% oxygen.
Multiplace Chambers: These larger chambers can accommodate multiple patients simultaneously, along with medical staff. Patients inside a multiplace chamber breathe 100% oxygen through masks or hoods, while the chamber itself is pressurized with compressed air.

Regardless of the type, both must meet FDA standards to be legally marketed for medical use. Knowing which type of chamber a facility uses can also be helpful for patients. More information on types of chambers can be found on resources like Types of Hyperbaric Chambers.

The Role of Manufacturers and Clinics

Manufacturers are responsible for submitting 510(k) notifications to the FDA to demonstrate the safety and effectiveness of their hyperbaric chambers. Once cleared, these devices can be legally marketed and sold in the U.S. Clinics and medical facilities that offer HBOT are then responsible for acquiring and using FDA-cleared devices. This ensures that the equipment they use for patient treatment meets established regulatory requirements. When we assess a facility, the use of FDA-cleared equipment is a primary factor in our evaluation of their adherence to safety standards. This commitment to using regulated devices is a cornerstone of responsible hyperbaric medicine practice.

What are the Risks and Side Effects of HBOT?

While hyperbaric oxygen therapy (HBOT) is a valuable treatment for many conditions, like any medical procedure, it carries potential risks and side effects. It is crucial for patients and practitioners to be fully aware of these possibilities to ensure informed consent and appropriate management. The Undersea & Hyperbaric Medical Society (UHMS) acknowledges these inherent risks, emphasizing the importance of careful patient selection and adherence to established protocols. Our analysis consistently highlights the need for transparent communication regarding both the benefits and potential drawbacks of HBOT.

General Considerations for HBOT Risks

The UHMS, in the preface to its 13th Edition of "Hyperbaric Oxygen Therapy Indications," includes an important disclaimer regarding responsibility and risk. Lindell K. Weaver MD, Chair and Editor, states, "No responsibility is assumed by the Publisher or Editor for any injury and or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, product, instructions, or ideas contained in the material herein. No suggested test or procedure should be carried out unless, in the reader’s judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that the independent verification of diagnoses and drug dosages be made." This statement serves as a reminder that healthcare decisions, including the use of HBOT, always involve a careful assessment of risks versus benefits, and that the medical field is constantly evolving.

Common Side Effects

Many side effects of HBOT are mild and temporary. These can include:

Ear and Sinus Barotrauma: This is the most common side effect, caused by pressure changes affecting the ears and sinuses. Patients may experience ear pain or a feeling of fullness. Techniques similar to those used by divers, like yawning or swallowing, can help equalize pressure.
Temporary Vision Changes: Some patients may experience temporary changes in vision, typically nearsightedness, which usually resolves after treatment.
Fatigue: Feeling tired after a session is not uncommon.

These common side effects are usually manageable and discussed with patients before treatment begins.

More Serious, Less Common Risks

While rare, more serious risks associated with HBOT can occur:

Oxygen Toxicity: Breathing 100% oxygen under pressure for extended periods can lead to oxygen toxicity, affecting the central nervous system or lungs. Symptoms can include seizures, coughing, or shortness of breath. Hyperbaric protocols are designed to minimize this risk by controlling pressure and duration of oxygen exposure.
Pulmonary Barotrauma: This involves injury to the lungs due as a result of pressure changes. It is a rare but serious complication, especially if a patient holds their breath during ascent. This risk is managed by careful patient screening and instruction on breathing techniques.
Claustrophobia: Being in a confined space, particularly in monoplace chambers, can trigger claustrophobia in some individuals. Facilities often offer strategies to help manage this, such as providing entertainment or sedatives if appropriate.
Worsening of Pre-existing Conditions: In some cases, HBOT could potentially worsen certain pre-existing conditions, though this is carefully evaluated during patient screening.

Importance of Medical Oversight and Verification

The UHMS statement also stresses the need for "independent verification of diagnoses and drug dosages." This highlights that HBOT should always be administered under the direct supervision of qualified medical professionals who are trained in hyperbaric medicine. They are responsible for:

Patient Selection: Carefully screening patients to ensure they are appropriate candidates for HBOT and that the benefits outweigh the risks for their specific condition.
Protocol Adherence: Following established UHMS guidelines and treatment protocols for specific indications, including pressure levels, duration of sessions, and number of treatments.
Monitoring and Management: Closely monitoring patients during and after HBOT sessions for any signs of adverse reactions and being prepared to manage emergencies.
Medication Review: Ensuring that any medications a patient is taking are compatible with HBOT and do not increase the risk of side effects.

Given the "rapid advances in the medical sciences," ongoing education and vigilance are essential for hyperbaric medicine practitioners. By understanding and mitigating these risks, and by adhering to expert-driven guidelines, HBOT can be delivered as safely and effectively as possible. Our commitment is to provide information that supports this careful, informed approach to hyperbaric care.

Reporting Adverse Events

Despite careful management, adverse events can still occur. It is crucial for both patients and healthcare providers to understand the process for reporting these events to regulatory bodies like the FDA. Reporting helps the FDA track device performance, identify potential safety issues, and inform future guidelines. This feedback loop is vital for continuous improvement in medical device safety and patient care. The FDA's MedWatch program is typically the channel through which medical device adverse events are reported, allowing for systematic collection and analysis of safety data.

Frequently Asked Questions

What is the main purpose of hyperbaric oxygen therapy?

The main purpose of hyperbaric oxygen therapy (HBOT) is to significantly increase the amount of oxygen dissolved in the body's blood plasma and other fluids. By breathing 100% oxygen in a pressurized chamber, the body absorbs far more oxygen than it would at normal atmospheric pressure. This enhanced oxygen delivery helps to promote healing, fight infections, reduce swelling, and support tissue survival, particularly in areas where blood flow is compromised. For example, HBOT is used for conditions like carbon monoxide poisoning and non-healing wounds.

How many conditions are officially recognized by the UHMS for HBOT?

The Undersea & Hyperbaric Medical Society (UHMS) officially recognizes 14 primary conditions for which hyperbaric oxygen therapy is an accepted treatment. These conditions are detailed in the UHMS's "Hyperbaric Oxygen Therapy Indications," 14th Edition. This comprehensive list includes a range of acute and chronic conditions, such as air or gas embolism, decompression sickness, severe anemia, and delayed radiation injuries. The UHMS regularly updates this list based on scientific evidence and clinical consensus to ensure best practices.

Can hyperbaric oxygen therapy treat gas embolism?

Yes, hyperbaric oxygen therapy is a primary and highly effective treatment for gas embolism. Gas embolism occurs when gas bubbles enter arteries or veins, which can be life-threatening. HBOT works by increasing the pressure around the body, which physically shrinks the gas bubbles, making them less obstructive. Additionally, the high concentration of oxygen helps to flush inert gases like nitrogen from the body and provides vital oxygen to tissues that may have been deprived due to the embolism. Richard E. Moon notes that pulmonary barotrauma and gas embolism due to breath-holding can occur after an ascent of as little as one meter.

Why does the FDA recommend UHMS-accredited facilities?

The FDA recommends UHMS-accredited facilities to ensure that patients receive hyperbaric oxygen therapy in environments that meet high standards for safety and efficacy. UHMS accreditation signifies that a facility adheres to rigorous protocols for equipment maintenance, staff training, patient care, and emergency preparedness. This recommendation helps patients identify reputable providers and ensures that HBOT is administered according to established, evidence-based guidelines. The FDA's endorsement highlights the UHMS's role in setting benchmarks for quality in hyperbaric medicine.

Where can I find a list of FDA-cleared hyperbaric devices?

You can find a list of FDA-cleared hyperbaric devices by searching the FDA's 510(k) Premarket Notification database. This online database contains information on medical devices that have been reviewed by the FDA and found to be substantially equivalent to legally marketed predicate devices, indicating their safety and effectiveness. By using search terms like "hyperbaric chamber" or specific manufacturer names, you can identify devices that have received FDA clearance. For instance, a specific 510(k) premarket notification can be found by searching for an ID like 'k021690'.